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Summary
Cladribine (CdA), an oral prodrug approved for the treatment of relapsing 
multiple sclerosis, selectively depletes lymphocytes. CdA passes the blood–
brain barrier, suggesting a potential effect on central nervous system (CNS) 
resident cells. We examined if CdA modifies the phenotype and function 
of naive and activated primary mouse microglia, when applied in the 
concentrations 0·1–1 μM that putatively overlap human cerebrospinal fluid 
(CSF) concentrations. Primary microglia cultures without stimulation or 
in the presence of proinflammatory lipopolysaccharide (LPS) or anti- 
inflammatory interleukin (IL)-4 were treated with different concentrations 
of CdA for 24  h. Viability was assessed by MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] assay. Phagocytotic ability and 
morphology were examined by flow cytometry and random migration 
using IncuCyte Zoom and TrackMate. Change in gene expression was ex-
amined by quantitative polymerase chain reaction (qPCR) and protein 
secretion by Meso Scale Discovery. We found that LPS and IL-4 up-regulated 
deoxycytidine kinase (DCK) expression. Only activated microglia were af-
fected by CdA, and this was unrelated to viability. CdA 0·1–1 μM signifi-
cantly reduced granularity, phagocytotic ability and random migration of 
activated microglia. CdA 10 μM increased the IL-4-induced gene expression 
of arginase 1 (Arg1) and LPS-induced expression of IL-1β, tumor necrosis 
factor (TNF), inducible nitric oxide synthase (iNOS) and Arg1, but protein 
secretion remained unaffected. CdA 10  μM potentiated the increased ex-
pression of anti-inflammatory TNF receptor 2 (TNF-R2) but not TNF-R1 
induced by LPS. This suggests that microglia acquire a less activated phe-
notype when treated with 0·1–1 μM CdA that putatively overlaps human 
CSF concentrations. This may be related to the up-regulated gene expres-
sion of DCK upon activation, and suggests a potential alternative mecha-
nism of CdA with direct effect on CNS resident cells.
Keywords: cladribine, deoxycytidine kinase, microglia, migration, multiple 
sclerosis, phagocytosis, viability
Introduction
Cladribine (CdA), also known as 2-chlorodeoxyadenosine, 
is a synthetic deoxyadenosine analogue that selectively depletes 
lymphocytes [1–3]. CdA is a prodrug, and accumulation of 
the active drug ‘CdA triphosphate’ depends upon the ratio 
of deoxycytidine kinase (DCK), that catalyzes the first of 
three phosphorylation steps, and 5′-nucleotidases (5′-NTases), 
that convert phosphorylated cladribine to cladribine nucleo-
side, as CdA cannot be degraded by adenosine deaminase 
(ADA). This resistance to ADA-mediated degradation results 
in apoptosis in cells with a high DCK to 5′-NTase ratio 
such as lymphocytes, due to accumulation of CdA triphos-
phate. In dividing lymphocytes, CdA triphosphate affects 
DNA synthesis and repair by inhibition of ribonucleotide 
reductase and the formation of deoxynucleotides. 
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Furthermore, CdA triphosphate competes with deoxyadeno-
sine triphosphate for incorporation into DNA by DNA 
polymerases. In resting cells, CdA triphosphate induces DNA 
strand breaks, which leads to the activation of poly (ADP-
ribose) polymerase and depletion of nicotinamide adenine 
dinucleotide and adenosine triphosphate from the cells [2,3].
Cladribine tablets have been approved for the treatment 
of relapsing multiple sclerosis (MS), based in part on a 
placebo-controlled, double-blind, multicenter Phase III trial 
[CLAdRIbine Tablets treating MS orally (CLARITY)]. In 
this trial, 3·5 mg/kg oral CdA reduced the annual relapse 
rate by approximately 57% [4], and the relative reduction 
in the risk of 3-month sustained progression of disability 
was 33% compared to placebo. The mean number of active 
T2 lesions on magnetic resonance imaging (MRI) was reduced 
by 73·4% [4]. The extension of the Phase III trial showed 
a durable effect on MRI and clinical outcomes [5,6].
The dose of 3·5  mg/kg CdA applied orally in short 
treatment cycles causes a short-term lymphocyte depletion 
followed by immune reconstitution [7]. However, CdA 
passes the blood–brain barrier (BBB), and gives rise to 
25% of the plasma concentration in the cerebrospinal fluid 
(CSF) resulting in a maximum CSF concentration of 
0·019–0·025  μM [2,3], and this may suggest a potential 
effect on central nervous system (CNS) resident cells.
Microglia comprise 10–15% of all glial cells in the CNS 
[8]. Proinflammatory microglia secrete proinflammatory 
cytokines, chemokines, and reactive oxygen and nitrogen 
species, which are toxic for oligodendrocytes and neurons 
[9,10]. Lipopolysaccharides (LPS) induce a proinflammatory 
phenotype of microglia characterized by the expression of 
interleukin (IL)-1β, IL-6, major histocompatibility complex 
II (MHC II), tumor necrosis factor (TNF) and inducible 
nitric oxide synthase (iNOS) [11,12]. Microglia also exert 
neuroprotective and repairing functions, and can produce 
neurotrophic factors and anti-inflammatory cytokines 
[11,13,14]. The anti-inflammatory cytokine IL-4 induces the 
anti-inflammatory phenotype characterized by arginase 1 
(Arg1) and IL-10 expression, among others [11,12,15].
Data concerning the effect of CdA on microglia are 
scarce [16]. When investigating the effect of the drug in 
murine cells, higher CdA concentrations are required as 
the activity of DCK is 10 times lower in mice than in 
humans [17,18]. Here, we examined the effect of CdA on 
the phenotype and function of naive and activated mouse 
microglia in concentrations that putatively overlap with 
the levels in the human CSF.
Materials and methods
Animals
C57BL/6 mice were obtained from Taconic Ltd (Ry, 
Denmark). Mice were bred at the Biomedical Laboratory, 
University of Southern Denmark, according to protocols 
and guidelines approved by the Danish Animal Experiments 
Inspectorate (approval no. 2014-15-00369). Animal experi-
ments complied with the European Union (EU) Directive 
2010/63/EU for animal experiments.
Microglia cell culture
Mixed primary glial cell cultures were prepared by enzy-
matic dissociation of postnatal P0–P5 mouse brains using 
the neural tissue dissociation kit (P) (Miltenyi Biotec, 
Odense, Denmark; 130-092-628). The cells were allowed 
to proliferate for 10  days prior to isolation of microglia 
by the ‘shake off ’ method [19]. The isolated microglia 
were, on average, 95% pure, when characterized as CD11b+/
CD45low on the flow cytometer (BDTM LSR II; BD 
Biosciences, San Jose, CA, USA).
In-vitro stimulation of microglia
CdA powder was provided by Merck. CdA was dissolved 
in dimethylsulfoxide (DMSO) (Sigma-Aldrich, St Louis, 
MO, USA; D2438). Microglia were treated with 0·2% 
DMSO, LPS (10  ng/ml) (Sigma-Aldrich; L2630), DMSO 
and LPS, one of four concentrations of CdA (0·01  μM, 
0·1  μM, 1 μM and 10  μM) alone or in combination 
with LPS for 24  hours. For migration, the cells were 
stimulated immediately before placement in the IncuCyte. 
Microglia were stimulated with IL-4 (20  ng/ml) or LPS 
(10  ng/ml) alone or together with CdA for 24  h for 
quantitative polymerase chain reaction (qPCR) and Meso 
Scale.
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] viability assay
MTT solution (0·5  mg/ml) (Sigma-Aldrich; M0283) was 
added to LPS- and CdA-pretreated microglia for 4  h. The 
absorbance was measured by a microplate reader (Molecular 
Devices, San Jose, CA, USA; 6465).
Phagocytosis assay, size and granularity
Microglia were incubated with fluorescent latex beads and 
analyzed by flow cytometry, as described previously [20]. 
Fluorescent latex beads (Polysciences, Inc., Warrington, PA, 
USA; 17154-10) were added to LPS- and CdA-treated 
microglia for 40  min at 37°C (sample) and 4°C (control). 
Cytochalasin D (5  μg/ml) was applied prior to addition 
of the beads as negative control. Phagocytosis was stopped 
by placing the cells on ice. Cells were detached using 
0·2% Trypsin-ethylenediamine tetraacetic acid (EDTA) and 
analyzed by flow cytometry and BD FACSDiva version 
8.0.1 software. Microglia size and granularity were assessed 
by flow cytometry and BD FACSDiva version 8.0.1 software 
by measuring forward- (FSC) and side-scatter (SSC), 
respectively.
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Random migration assay
Microglia were seeded at a density of 12  000 cells/well 
in a poly-D-lysine (PDL)-coated 96-well ImageLock plate 
(Essen Bioscience, Ann Arbor, MI, USA; 4379) and stained 
with CellTracker Red CMTPX fluorescent probe (4·5 μM) 
(Life Technologies, Carlsbad, CA, USA). DMSO (0·2%), 
LPS (10  ng/ml) and CdA in different concentrations 
alone (0·1–10  μM) or together with LPS were added, 
and cells were placed in the IncuCyte Zoom live cell 
imaging system (Essen BioScience). Pictures were taken 
every 20  min for 24  h. Single-cell motility was quanti-
fied using the Fiji plugin TrackMate for semi-automated 
particle tracking [21]. To detect individual cells in 
TrackMate, the Laplacian of Gaussian (LoG) detector 
with estimated spot diameter of 24·12 μm and a thresh-
old of 0·3 was used. The simple linear assignment problem 
(LAP) tracker with a linking maximum distance of 
60  μm, a gap-closing maximum distance of 15  μm and 
a gap-closing maximum distance of 2 was used to track 
cell migration through the time–course films. The number 
of spots in track was set to 71·09 to exclude cells, which 
were not detectable throughout the films from the 
analysis.
RNA extraction and quantitative PCR
RNA was extracted using RNeasy micro kit (Qiagen, 
Copenhagen, Denmark) and reverse-transcribed using a 
high-capacity cDNA reverse transcription kit (Applied 
Biosystems, Foster city, CA, USA; 4374966). qPCR was 
performed on the Bio-Rad CFX ConnectTM real-time sys-
tem (Software Bio-Rad CFX Manager version 3.1) using 
SYBR green chemistry (Thermo Fisher Scientific, Fremont, 
CA, USA) and corresponding primers (Supporting infor-
mation, Table S1). The expression levels are reported 
relative to the geometric mean of glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) and hypoxanthine phos-
phoribosyltransferase 1 (HPRT1).
Meso Scale Discovery (MSD) multiplex analysis
Cytokine levels in the microglia cell culture media were 
measured with the Meso Scale Discovery (MSD, Kenilworth, 
NJ, USA) proinflammatory mouse V-Plex Plus kit [21].
Statistics
The statistical analyses were performed in Prism version 
6.01 (GraphPad, San Diego, CA, USA) using one-way 
analysis of variance (ANOVA) followed by Sidak’s or 
Dunnett’s multiple comparisons tests or by unpaired t-test 
with Welch’s correction. Outliers were removed using the 
robust regression and outlier removal (ROUT) method 
(Q  =  1%). Differences among means with P  <  0·05 were 
accepted as statistically significant, while differences among 
means with 0·05 < P < 0·10 were accepted as representing 
tendencies of difference.
Results
Cladribine (0·01–10 μM) does not influence the 
viability of naive or LPS-stimulated microglia
Microglia were treated with DMSO, LPS, DMSO and LPS 
and different concentrations of CdA and CdA together 
with LPS for 24  h before incubation with MTT. DMSO, 
LPS and their combination did not affect the viability of 
microglia compared to control (Fig. 1). CdA in the applied 
concentration range (0·01–10 μM) did not affect the viability 
of naive and LPS-stimulated microglia compared to DMSO 
control (Fig. 1).
Fig. 1. The effect of cladribine on the viability of naive and lipopolysaccharide (LPS)-stimulated microglia. Microglia were treated with 
dimethylsulfoxide (DMSO) (0·2%), LPS (10 ng/ml), DMSO and LPS, different concentrations of cladribine (CdA) (0·01 μM, 0·1 μM, 1 μM and 10 μM) 
and different concentrations of CdA together with LPS for 24 h, followed by an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
assay. The results [mean ± standard deviation (s.d.)] are shown relative to DMSO control. n = 4–5 in each group, one-way analysis of variance 
(ANOVA) followed by multiple comparison tests.
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Cladribine (0·1 μM) decreases the granularity of 
LPS-stimulated microglia
The size and granularity of naive and LPS-stimulated 
microglia treated with CdA were investigated by flow 
cytometry (Fig. 2). LPS stimulation increased the SSC 
mean fluorescence intensity (MFI) indicating increased 
cellular granularity (Fig. 2a,b). We observed a trend towards 
reduced granularity of LPS-stimulated microglia treated 
with 0·1  μM CdA (P  =  0·07), while CdA did not influ-
ence the granularity of naive microglia (Fig. 2a,b). No 
apparent difference in cell size reflected by FSC MFI was 
observed (Fig. 2a,c).
Cladribine (0·1–1 μM) decreases the phagocytotic 
ability of LPS-stimulated microglia
To investigate the effect of CdA on phagocytosis by naive 
and LPS-stimulated microglia, the cells were incubated 
with fluorescent latex beads and analyzed by flow cytom-
etry. LPS stimulation significantly increased phagocytosis 
compared to control, while treatment with cytochalasin 
D, an inhibitor of actin polymerization, reduced phago-
cytosis (Fig. 3a). CdA in the range of 0·1–1  μM signifi-
cantly decreased phagocytosis by LPS-stimulated microglia, 
while treatment with CdA (0·01–10  μM) did not affect 
phagocytosis by naive microglia compared to DMSO con-
trol (Fig. 3a).
Cladribine (0·1–1 μM) decreases the motility of 
LPS-stimulated microglia
Microglia motility after CdA treatment was measured by 
random migration: track displacement refers to the bee-
line distance the cells migrate in 24  h, while the total 
distance traveled is the actual distance covered by the 
cells. Microglia were stained with cell tracker and treated 
with DMSO, LPS, DMSO and LPS, different concentrations 
of CdA or CdA together with LPS. Films were recorded, 
and the track displacement and total distance traveled by 
the microglia were determined.
The microglia track displacement was significantly 
increased by LPS stimulation compared to untreated control 
(Fig. 3b). Treatment with CdA 0·1  μM significantly 
decreased the track displacement of LPS-stimulated micro-
glia, whereas CdA (0·1–10  μM) did not alter the track 
displacement of naive microglia compared to DMSO control 
(Fig. 3b).
The total distance travelled by microglia was not sig-
nificantly increased by LPS stimulation, although a trend 
was observed (P  =  0·07) (Fig. 3c). CdA in the range 
of 0.1-1 µM significantly decreased the total distance 
travelled by LPS-stimulated microglia (Fig. 3c). CdA 
0·1–10  μM did not have an effect on the total distance 
traveled by naive microglia compared to DMSO control 
(Fig. 3c).
Cladribine (10 μM) alters expression but not secretion 
of pro- and anti-inflammatory molecules by activated 
microglia
Next, we investigated the effect of CdA on the relative 
mRNA expression and protein secretion of selected pro- 
and anti-inflammatory markers after stimulation with LPS 
or IL-4 for 24  h. The expression of IL-1β, TNF, IL-10, 
TNF-receptors, iNOS and Arg1 were examined by qPCR. 
The secretion of IL-1β, TNF and IL-10 were investigated 
by Meso Scale Discovery.
LPS stimulation resulted in an increased mRNA expres-
sion of IL-1β, TNF and IL-10 compared to control 
(Fig. 4a). Treatment with CdA 10  μM further increased 
the mRNA expression of IL-1β and TNF in LPS-stimulated 
cells (Fig. 4a). CdA (0.01-10µM) did not affect the expres-
sion of these cytokines in naive microglia (data not shown).
The protein secretion of IL-1β, TNF and IL-10 was increased 
by LPS stimulation (Fig. 4b). In contrast, CdA (0·1–10  μM) 
did not affect the secretion of IL-1β, TNF and IL-10 from 
LPS-stimulated (Fig. 4b) or naive microglia (data not shown).
LPS stimulation increased the mRNA expression of 
both TNF-R1 and TNF-R2 compared to control. CdA 
10  μM further increased the expression of TNF-R2 but 
not TNF-R1 (Fig. 5). CdA (0·01–10  μM) did not affect 
the expression of TNF receptors in naive microglia (data 
not shown).
LPS stimulation resulted in a significantly increased 
expression of iNOS and Arg1 mRNA compared to the 
untreated control, but these were reduced by DMSO co-
treatment (Fig. 6). Co-treatment with 10  μM CdA sig-
nificantly increased the expression of iNOS and Arg1 in 
LPS-stimulated microglia compared to DMSO control 
(Fig. 6). CdA did not affect the mRNA expression of 
iNOS or Arg1 in naive microglia (data not shown).
IL-4 stimulation for 24  h only increased Arg1 expres-
sion, whereas no changes were observed in mRNA expres-
sion of IL-1β, TNF, IL-10, TNF-R1 and TNF-R2. 
Furthermore, the expression of these genes was not affected 
by CdA co-treatment (Fig. 7 and Supporting information, 
Figs S1, S2). IL-4 did not induce the expression of iNOS 
(data not shown). Similarly, no difference was observed 
in the secretion of IL-1β, TNF and IL-10 from IL-4-
stimulated and CdA co-treated microglia (Supporting 
information, Fig. S1).
LPS and IL-4 increase the mRNA expression of the 
enzyme DCK
We examined the mRNA expression of DCK in naive and 
activated microglia treated with CdA. LPS stimulation 
L. Ø. Jørgensen et al.
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increased the expression of DCK, while IL-4 stimulation 
resulted in a similar trend compared to DMSO control 
(P  =  0.08) (Fig. 8a,b). CdA (0·01–10  μM) did not change 
the increased expression induced by LPS and IL-4 
(Fig. 8a,b). The expression of DCK was not affected by 
CdA (0·01–10 μM) in naive microglia either (data not shown).
Discussion
To determine the effect of CdA on murine microglia, 
we examined phenotypical and functional properties of 
naïve, LPS- and IL-4-stimulated microglia treated with 
different concentrations of CdA for 24  h. We found 
Fig. 2. The effect of cladribine on microglia granularity and size. Microglia were treated with dimethylsulfoxide (DMSO) (0·2%), lipopolysaccharide 
(LPS) (10 ng/ml), DMSO and LPS, different concentrations of cladribine (CdA) (0·01 μM, 0·1 μM, 1 μM and 10 μM), and different concentrations of 
CdA together with LPS for 24 h. (a) A representative example of size [forward-scatter (FSC)] and granularity [side-scatter (SSC)] of microglia by flow 
cytometry. (b) The effect of CdA on the granularity (SSC) of naive and LPS-stimulated microglia relative to DMSO control. (c) The effect of CdA on 
the size (FSC) of naive and LPS-stimulated microglia relative to DMSO control. ***P ≤ 0·001, n = 3–4 in each group, one-way analysis of variance 
(ANOVA) followed by multiple comparison tests, mean ± standard deviation (s.d.).
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Fig. 3. The effect of cladribine on the phagocytotic ability and random migration of microglia. (a) Phagocytosis was quantified after microglia were 
treated with dimethylsulfoxide (DMSO) (0·2%), lipopolysaccharide (LPS) (10 ng/ml), DMSO and LPS, different concentrations of cladribine (CdA) 
(0·01 μM, 0·1 μM, 1 μM and 10 μM), and different concentrations of CdA together with LPS for 24 h. Fluorescent latex beads were added to the cell 
media for 40 min. As negative control, microglia were treated with cytochalasin D (5 μg/ml) for 30 min before addition of latex beads. The cells were 
analyzed by flow cytometry, and the phagocytotic ability was quantified by mean fluorescent intensity (MFI) and presented relative to DMSO control. 
(b) Track displacement was quantified by analysis of timelapse videos using TrackMate after microglia were treated with DMSO (0·2%), LPS  
(10 ng/ml), DMSO and LPS, different concentrations of CdA (0·1 μM, 1 μM and 10 μM) and different concentrations of CdA together with LPS for  
24 h. The results are shown relative to DMSO control. (c) Total distance travelled was quantified by analysis of timelapse videos using TrackMate after 
microglia were treated with DMSO (0·2%), LPS (10 ng/ml), DMSO and LPS, different concentrations of CdA (0·1 μM, 1 μM and 10 μM) and different 
concentrations of CdA together with LPS for 24 h. The results are shown relative to DMSO control. *P ≤ 0·05, ****P ≤ 0·0001, n = 3–5 in each group, 
one-way analysis of variance (ANOVA) followed by multiple comparison tests, mean ± standard deviation (s.d.).
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Fig. 4. The effect of cladribine on the mRNA expression and protein secretion of cytokines by lipopolysaccharide (LPS)-stimulated microglia. (a) 
mRNA expression of interleukin (IL)-1β, tumor necrosis factor (TNF) and IL-10 was quantified by quantitative polymerase chain reaction (qPCR) 
after microglia were treated with dimethylsulfoxide (DMSO) (0·2%), LPS (10 ng/ml), DMSO and LPS and different concentrations of cladribine (CdA) 
(0·01 μM, 0·1 μM, 1 μM and 10 μM) together with LPS for 24 h. The expression is shown relative to DMSO control. (b) The protein concentration of 
IL-1β, TNF and IL-10 in the microglia cell culture supernatant was quantified by Meso Scale. The microglia were treated with DMSO (0·2%), DMSO 
and LPS, and different concentrations of CdA (0·1 μM, 1 μM and 10 μM) together with LPS for 24 h. *P ≤ 0·05, **P ≤ 0·01, ***P ≤ 0·001, 
****P ≤ 0·0001, n = 4 in each group, unpaired t-test with Welch’s correction and one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparison test, mean ± standard deviation (s.d.).
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that CdA only affects stimulated and not naive microglia. 
Furthermore, different concentrations of CdA influenced 
different aspects of microglia function. CdA concentra-
tions putatively overlapping with CSF concentrations in 
humans (0.1-1 µM) significantly reduced the granularity, 
phagocytotic ability and motility of LPS-stimulated 
microglia, while a higher CdA concentration (10  μM) 
increased the mRNA expression of pro- and anti-inflam-
matory molecules, but not protein secretion. In addition, 
we found that activation of microglia increased the 
expression of DCK responsible for the activation of the 
prodrug.
CdA can cross the BBB and thereby potentially exert 
an effect on CNS resident microglia [2,3]. The maximum 
plasma concentration of CdA after administration of a 
10-mg tablet is in the range of 0·07–0·1  μM [22]. As the 
CSF concentration is 25% of the plasma concentration 
[2,3], the maximum CSF concentration attainable is approxi-
mately 0·019–0.025  μM. The active form of CdA is CdA 
triphosphate, which is the phosphorylated form of the 
drug [2,3]. The first step of this process is catalyzed by 
DCK, the activity of which is 10 times lower in mice 
than humans [17,18]. The maximum CdA concentration 
detected in the CSF of patients thus may correspond to 
murine concentrations in the range of 0.1-1 µM. Therefore, 
we applied CdA concentrations of 0·01–10  μM in this 
study of murine microglia.
We first investigated whether the applied CdA concen-
trations were toxic to microglia. We found that the viability 
of microglia was not affected during the short culture 
Fig. 5. The effect of cladribine on the mRNA expression of tumor necrosis factor receptors (TNF-R) in lipopolysaccharide (LPS)-stimulated microglia. 
mRNA expression of TNF-R1 and TNF-R2 was quantified by quantitative polymerase chain reaction (qPCR) after microglia were treated with 
dimethylsulfoxide (DMSO) (0·2%), LPS (10 ng/ml), DMSO and LPS, and different concentrations of cladribine (CdA) (0·01 μM, 0·1 μM, 1 μM and 
10 μM) together with LPS for 24 h. The expression is shown relative to DMSO control. *P ≤ 0·05, **P ≤ 0·01, ***P ≤ 0·001, n = 4 in each group, one-way 
analysis of variance (ANOVA) followed by multiple comparison tests, mean ± standard deviation (s.d.).
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conditions, similar to a previous study that applied the 
intravenous compound to rat microglia cultures [16]. 
Therefore, we considered that using these concentrations 
for short-term stimulation would not have a depleting 
effect on the cells.
LPS stimulation resulted in a morphological change 
of microglia characterized by an increase in SSC and 
thus a more granular morphology, as expected. 
Co-treatment with CdA 0·1  μM showed a tendency 
towards decreased granularity, suggesting that CdA may 
have an effect on the functional properties of microglia. 
Further experiments with larger sample size may confirm 
this trend.
We then examined the phagocytotic ability and motil-
ity of microglia. We found that LPS stimulation 
significantly increased the phagocytotic ability of micro-
glia, which correlated with the proinflammatory pheno-
type induced by LPS. Such increased phagocytotic ability 
of LPS-stimulated microglia was decreased by CdA in 
the range of 0.1-1 µM. Furthermore, the decrease in 
phagocytosis by CdA corresponds to the observed 
decreased granularity of microglia. CdA had no effect 
on naive microglia, which is consistent with findings of 
former studies performed on rat microglia [16], and 
murine dendritic cells [23].
Microglia motility is important for maintaining CNS 
homeostasis via interaction with other cells and scanning 
of the CNS environment [8,11,24,25]. We measured the 
random migration by (i) track displacement, i.e. the distance 
from start to end point, and (ii) total distance travelled 
Fig. 6. The effect of cladribine on the mRNA expression of arginase 1 (Arg1) and inducible nitric oxide synthase (iNOS) in lipopolysaccharide 
(LPS)-stimulated microglia. mRNA expression of arginase 1 and iNOS was quantified by quantitative polymerase chain reaction (qPCR) after 
microglia were treated with dimethylsulfoxide (DMSO) (0·2%), LPS (10 ng/ml), DMSO and LPS and different concentrations of cladribine (CdA) 
(0·01 μM, 0·1 μM, 1 μM and 10 μM) together with LPS for 24 h. The expression is shown relative to DMSO control. **P ≤ 0·01, ***P ≤ 0·001, n = 4 in 
each group, one-way analysis of variance (ANOVA) followed by multiple comparison tests, mean ± standard deviation (s.d.).
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that includes twists and turns and describes the patrolling 
of migrating cells. LPS stimulation significantly increased 
track displacement and showed a tendency towards increased 
total distance travelled. This is consistent with the acquisi-
tion of effector functions induced by LPS and a tendency 
towards increased patrolling of the surroundings. In contrast 
to random migration, LPS decreased chemotactic migration 
of rat microglia [26]. We also found that CdA (0.1-10 µM) 
did not affect the motility of resting microglia.
Observing changes in morphology, phagocytotic ability 
and migration of LPS-stimulated microglia, we next examined 
how CdA alters gene expression and protein secretion of 
microglia stimulated with LPS and with anti-inflammatory 
IL-4. LPS increased the expression of pro- and anti-inflam-
matory markers, consistent with a recently published study 
[26]. Co-treatment with CdA in the high concentration 
(10  μM) increased the gene expression of both pro- and 
anti-inflammatory markers, such as IL-1β, TNF, iNOS, Arg1 
and TNF-R2, suggesting a potentiating effect on activated 
microglia. Interestingly, only the gene expression of anti-
inflammatory TNF-R2, but not the proinflammatory TNF-R1 
[27], was potentiated by CdA. The increased protein secretion 
of IL-1β, TNF and IL-10 induced by LPS was not further 
increased by CdA (0.1-10 µM), consistent with a previous 
study on rat microglia [16]. This suggests that CdA only 
affects gene expression but not protein secretion. We may 
speculate that accumulation of CdA in microglia may inter-
fere with RNA processing besides interference with DNA 
replication and this may alter translational mechanisms. 
Another possible explanation for the potentiating effect of 
CdA on gene expression but not on protein secretion is 
that the cytokines remain intracellularly. IL-1β may not be 
fully secreted under these conditions [28].
We also found that DMSO co-treatment reduced the 
expression of iNOS and Arg1 in LPS-stimulated microglia, 
while the expression of IL-1β, TNF and IL-10 remained 
unaffected. As the effect of DMSO on microglia has not 
been described, we speculate whether the applied DMSO 
concentration only affects the expression of enzymes, while 
higher concentrations may be required to affect the cytokine 
expression. This is supported by a study on LPS-stimulated 
bone marrow derived macrophages, in which a DMSO 
concentration of 0·25% reduced the expression of iNOS 
similarly to our experiments [29].
We also found that IL-4 stimulation resulted in an 
increased gene expression only of Arg1 but it was not 
affected by CdA co-treatment. This could indicate that 
IL-4 is a less potent stimulus in the short term, and 
microglia may not be sufficiently activated for the poten-
tiating effect of CdA. In summary, CdA in the applied 
concentration did not have an effect on cytokine secretion 
of activated or resting microglia in short-term primary 
cultures. The observed effect on gene expression was 
achieved by higher concentrations of CdA than may be 
expected in the human CSF during treatment.
Activation of microglia by LPS and IL-4 also increased 
the gene expression of DCK that phosphorylates CdA to 
its active form. This may suggest that activated microglia 
may increase their ability to respond to CdA. In lym-
phocytes, CdA interferes with DNA synthesis and repair 
resulting in depletion of both proliferating and resting 
cells [2,3]. The mechanism by which CdA affects microglia 
functions remains to be determined, and our data do not 
indicate microglia depletion in the short term. A previous 
study also suggested that an additional mechanism beside 
Fig. 7. The effect of cladribine on the mRNA expression of arginase 1 
(Arg1) in interleukin (IL)-4-stimulated microglia. mRNA expression of 
arginase 1 was quantified by quantitative polymerase chain reaction 
(qPCR) after microglia were treated with dimethylsulfoxide (DMSO) 
(0·2%), IL-4 (20 ng/ml), DMSO and IL-4, and different concentrations 
of cladribine (CdA) (0·01 μM, 0·1 μM, 1 μM and 10 μM) together with 
IL-4 for 24 h. The expression is shown relative to DMSO control. 
*P ≤ 0·05, n = 3–4 in each group, one-way analysis of variance 
(ANOVA) followed by multiple comparison tests, mean ± standard 
deviation (s.d.).
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depletion may be responsible for the effects on microglia, 
such as reduced proliferation [16]. In dendritic cells, the 
function of CdA is partially independent from its phos-
phorylation [23]; however, this may not be true in microglia, 
as the effect of CdA on proliferation was lost upon addi-
tion of a competitive substrate of DCK [16].
In summary, we found that CdA used in a concentra-
tion that may be reached in the human CSF during 
approved treatment of MS affected activated but not naive 
microglia; this may be related to the up-regulated gene 
expression of DCK upon activation. Co-treatment with 
CdA reduced the phagocytotic ability and random migra-
tion of activated microglia, while viability was not affected 
among the applied conditions. Although gene expression 
of both pro- and anti-inflammatory molecules was potenti-
ated by CdA, it was induced only by a higher 
concentration (10  μM) than should be expected in the 
CSF, and protein secretion was not altered. CdA also 
potentiated the gene expression of anti-inflammatory 
TNF-R2. These data suggest that, as well as depletion of 
peripheral lymphocytes, CdA may induce additional effects, 
particularly in CNS resident cells that contribute to its 
beneficial effects in MS. It could therefore be interesting 
to examine the effect of CdA on the morphology and 
function of microglia from mice exposed to cuprizone, 
as it induces activation of microglia in vivo [21,30,31].
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Fig. S1. The effect of cladribine on the mRNA expression 
and protein secretion of cytokines by IL-4-stimulated mi-
croglia. (a) mRNA expression of IL-1β, TNF and IL-10 
was quantified by qPCR after microglia were treated with 
DMSO (0·2%), IL-4 (20 ng/ml), DMSO and IL-4, and dif-
ferent concentrations of CdA (0·01 μM, 0·1 μM, 1 μM and 
10 μM) together with IL-4 for 24 hours. The expression is 
shown relative to DMSO control. (b) The protein concen-
tration of IL-1β, TNF and IL-10 in the microglia cell culture 
supernatant was quantified by Meso Scale. Microglia were 
treated with DMSO (0·2%), DMSO and IL-4 (20  ng/ml), 
and different concentrations of CdA (0·1  μM, 1  μM and 
10 μM) together with IL-4 for 24  hours. n  =  3-4 in each 
group, unpaired t test with Welch’s correction and one-way 
ANOVA followed by Dunnett’s multiple comparisons test, 
mean ± SD.
Fig. S2. The effect of cladribine on the mRNA expression of 
TNF receptors in IL-4-stimulated microglia. mRNA expres-
sion of TNF-R1 and TNF-R2 was quantified by qPCR after 
microglia were treated with DMSO (0·2%), IL-4 (20 ng/ml), 
DMSO and IL-4, and different concentrations of CdA 
(0·01 μM, 0·1 μM, 1 μM and 10 μM) together with IL-4 for 
24 hours. The expression is shown relative to DMSO control. 
n = 3-4 in each group, one-way ANOVA followed by multi-
ple comparisons tests, mean ± SD.
Table S1. Sequences or primer IDs of the oligonucleotides 
used for qPCR amplification.
